People searching for growth hormone therapy usually arrive with a story. They are in their forties, fifties or sixties, and something has shifted. Recovery from workouts takes twice as long. Belly fat is stubborn in a way it never was. Sleep is lighter, skin is thinner, and the person in the mirror looks tired even after a good week. Someone has mentioned that growth hormone declines with age, and a short search produces three very different kinds of results: clinics that advertise injectable HGH, clinics that advertise peptides with names that sound like laboratory codes, and clinics that offer something else entirely, often taken by mouth. The three are lumped together under one heading in search results, but they are not interchangeable. They answer to different laws, rest on different evidence and carry different risks.
This guide separates them. It treats prescription HGH, growth hormone releasing peptides and oral medical foods such as the Sarcotropin program as three doors into the same room, and it explains what is behind each one, who each one is actually for, what testing should come first, and how to ask questions that expose the difference between a careful program and a marketing claim. It is written for patients in the Phoenix area, but nothing about the biology or the regulation is local.
What growth hormone actually does in an adult
Growth hormone is made in the pituitary gland, a pea sized structure at the base of the brain. In children it drives growth. In adults its role shifts toward maintenance. It influences how the body partitions fuel between fat and lean tissue, supports bone turnover, affects connective tissue repair and plays a part in sleep quality and recovery. Many of its effects are mediated through insulin-like growth factor 1, usually written IGF-1, which is produced mainly in the liver in response to growth hormone and which is the number most often measured in a blood test.
Two features of this system matter for everything that follows. First, growth hormone is released in pulses, mostly at night during deep sleep and in smaller bursts after intense exercise or a long fast. A single blood sample of growth hormone itself is therefore almost meaningless, because it can be very high or very low depending on the minute it was drawn. That is why IGF-1, which changes slowly, serves as a stand in. Second, the system is governed by a feedback loop. The hypothalamus releases a signal called growth hormone releasing hormone, the pituitary responds by releasing growth hormone, and somatostatin from the hypothalamus acts as a brake. Any approach that adds growth hormone from outside bypasses the loop, while any approach that nudges the signal upstream works with it.
Output declines gradually from early adulthood, roughly a tenth to a seventh per decade according to commonly cited estimates, and falls faster in people with excess abdominal fat, poor sleep or untreated sleep apnea. This slow decline is sometimes called somatopause, and it is where much of the marketing energy sits. The key question is whether this normal age-related decline is a disease that needs replacement. Medicine, so far, has said no, and the rest of the guide follows from that.
Door one: prescription human growth hormone
Injectable recombinant HGH has been available since the 1980s, and it is a legitimate, life changing treatment for specific conditions. In adults, the approved uses include growth hormone deficiency that results from pituitary disease, hypothalamic disease, surgery, radiation or head injury, as well as childhood-onset deficiency that persists into adulthood. It is also approved for HIV related wasting and for certain patients with short bowel syndrome receiving specialized nutrition. In children it treats growth failure from several causes.
The regulation around HGH is among the most distinctive in medicine. Federal law makes it a crime to distribute or possess with intent to distribute human growth hormone for any use that is not approved by the Food and Drug Administration, and anti-aging is not an approved use. This is not a gray area created by an overcautious clinic. It is the reason that legitimate physicians do not prescribe HGH to healthy adults who want to feel younger, and the reason that any advertisement promising exactly that deserves a pause. A patient who is offered injectable HGH for general vitality should ask which approved diagnosis is being treated and how it was established.
That diagnosis is established with testing that is more demanding than most people expect. A low IGF-1 alone does not prove deficiency, because IGF-1 falls with age, with poor nutrition, with liver disease and with uncontrolled diabetes. Adult growth hormone deficiency is typically confirmed by a stimulation test, in which a trigger such as insulin-induced low blood sugar, glucagon or an oral agent called macimorelin is given and growth hormone is measured at timed intervals to see whether the pituitary can respond. These tests are done in endocrinology settings, often with monitoring, because some are uncomfortable or carry risk. People who have a known pituitary disorder, a history of brain surgery or radiation, or multiple other pituitary hormone deficiencies are the typical candidates.
For healthy older adults, the research on HGH is sobering. Systematic reviews of controlled trials have found that it increases lean body mass and decreases fat mass by modest amounts, on the order of a couple of kilograms each, without clear improvements in strength, exercise capacity or quality of life, and with a higher rate of side effects. Those include fluid retention, joint pain, carpal tunnel symptoms, breast enlargement in men and a tendency toward higher blood sugar and diabetes. Supraphysiologic dosing over long periods raises concern about acromegaly like changes, and the long term cancer question is not settled. The mismatch between promotional claims and trial results is the central reason mainstream endocrinology does not endorse HGH for aging.
Door two: growth hormone releasing peptides
The second door looks gentler because it works upstream. Instead of supplying growth hormone, these compounds prompt the pituitary to release its own. They fall into two broad families. Growth hormone releasing hormone analogs, such as sermorelin and tesamorelin, mimic the hypothalamic signal. Growth hormone secretagogues, a group that includes compounds like ipamorelin, act on a different receptor, the one stimulated by the hormone ghrelin, and also prompt release. They are often combined, on the theory that two signals together produce a stronger pulse.
Their regulatory histories vary, and that matters. Sermorelin was once an FDA approved drug used mainly as a diagnostic aid and for certain pediatric growth problems, and its manufacturer discontinued it in the late 2000s for business reasons, not safety reasons. It is now obtainable through compounding pharmacies. Tesamorelin is approved, but for a narrow purpose: reducing excess abdominal fat in HIV patients with lipodystrophy. Most of the other secretagogues in circulation are not approved for any use, are supplied by compounding or research suppliers and have a regulatory status that has shifted several times as the FDA has reviewed which substances compounding pharmacies may use. A patient considering this route should ask where the product is compounded, whether the pharmacy is licensed and inspected, and how purity is verified, because the risk with unapproved peptides is as much about manufacturing quality as about the molecule.
The theoretical appeal is real. A releasing peptide leaves the feedback loop intact, so the body’s own braking system can limit excess, and the pulses look closer to natural ones than a steady injection of HGH does. The evidence base is thinner than the appeal. Small studies show that these agents raise growth hormone and IGF-1 and can change body composition, but long term randomized trials in healthy adults with meaningful outcomes such as fractures, falls or cardiovascular events are lacking. Side effects reported include injection site reactions, flushing, headache, water retention and changes in blood sugar. Because these are injectables, they also require sterile technique and appropriate medical oversight.
Door three: oral medical foods and the Sarcotropin approach
The third door is the one that confuses people most, because the word “peptide” is sometimes applied loosely to products that are not injectables at all. The practice’s Sarcotropin therapy page describes the program as a physician-directed, orally administered medical food intended to support the body’s own growth hormone release. It is delivered through in-person consultation and ongoing care, not purchased online, and it is described as suitable for adults who have age related muscle loss, low energy or slower recovery.
To evaluate any product in this category, it helps to understand what a medical food is. Under federal law, a medical food is a specially formulated food intended to be used under physician supervision for the specific dietary management of a disease or condition that has distinctive nutritional requirements, and it must be based on recognized scientific principles. It is not a drug, it does not go through the drug approval process, and the FDA does not pre-approve it. That is neither good nor bad in itself. Many legitimate medical foods exist, for example for rare metabolic disorders. But it does mean that the usual shorthand of “FDA approved” does not apply to this class, and a patient should be wary of any material that treats the two categories as the same.
What would a patient fairly ask? Ask what the formulation contains, since a product that supports a hormone pathway through amino acids and nutrients can be evaluated ingredient by ingredient. Ask what condition it is being used to manage and what the clinic’s criteria for candidacy are. Ask what the evidence is for the specific formulation as opposed to its ingredients in general, because trials of arginine or other amino acids do not automatically carry over to a blend. And ask what outcome will be measured and when, so that the program has a way to show whether it is working.
Some of the biology behind the approach is reasonable. Certain amino acids given in large single doses can transiently raise growth hormone secretion. The effect is short lived, varies from person to person, and the studies that show it often use doses that cause stomach upset. Whether regular use of a lower dose blend meaningfully changes IGF-1 or body composition over months is a separate question that needs direct evidence. A fair statement of the situation is that the mechanism is plausible, the possible benefits are modest, the risk profile is likely lower than injected hormone, and the strength of evidence depends on the particular product. The page describes mild digestive discomfort as the most commonly reported side effect, usually in the first week or two, and that is consistent with how amino acid supplements generally behave.
How the three compare on the things that matter
Placed side by side, the doors differ along a handful of axes, and thinking in these terms keeps the conversation concrete.
On legality and regulation, prescription HGH is tightly restricted to approved diagnoses. Releasing peptides occupy a changing space where a few compounds are approved for narrow uses and most are compounded. Medical foods sit under food rules rather than drug rules and rely on physician supervision.
On evidence, HGH has strong evidence in true deficiency and mixed evidence with notable side effects in healthy older adults. Releasing peptides have physiologic evidence and small trials but few large outcome studies. Oral medical food formulations generally have the least product specific clinical research, though their ingredients may have it.
On risk, HGH carries the largest set of known adverse effects, particularly at doses that exceed physiologic need. Peptides carry moderate risks and manufacturing uncertainty. Oral formulations tend to produce the mildest effects, mostly digestive, and also the smallest expected benefit.
On monitoring, all three require baseline and follow-up testing. The fact that a product is taken by mouth does not make laboratory follow-up optional.
On cost and commitment, the programs differ, and patients should expect clear explanations in writing rather than open ended auto-renewing plans.
What to test before any of these, and why
Whichever door is considered, the starting point is the same: find out what is actually going on. A thoughtful evaluation looks at symptoms, medications, sleep, nutrition and exercise before it looks at hormones, because most complaints that lead people to growth hormone have common and treatable causes.
Laboratory work usually includes IGF-1, fasting glucose and hemoglobin A1c, a lipid panel, thyroid function, a complete metabolic panel including liver and kidney markers, and often sex hormones such as testosterone or estradiol. Vitamin D, ferritin and inflammatory markers add context. IGF-1 should be interpreted against age and sex specific reference ranges, and a mildly low value in a person over fifty is expected rather than alarming. The results are only one piece. A patient with a normal IGF-1 and obvious sleep deprivation will gain more from fixing sleep than from any hormone.
Sleep deserves a special emphasis because it is the single largest natural driver of growth hormone release. The majority of daily output occurs in slow wave sleep, and anything that shortens or fragments it, from alcohol to untreated sleep apnea to late-night screens, reduces output. The practice’s discussion of how much sleep you are actually getting and its article on the link between menopause and insomnia both touch on this, and the experience of many clinicians is that sleep correction produces improvement in energy and recovery that patients had attributed to hormones. Exercise is the second driver, with heavy resistance training and high intensity intervals producing measurable pulses. Fasting and weight loss increase growth hormone secretion, and obesity suppresses it, which is why changes in body composition can improve the signal without any supplement at all.
Metabolic health matters just as much. Insulin resistance blunts growth hormone secretion and is associated with central fat gain. Anyone who suspects it can read the clinic’s explanation of what it means to be insulin resistant, and a patient on a physician supervised weight program may find that improving insulin sensitivity changes the picture before anything else is added. Growth hormone raises blood sugar, so people with prediabetes or diabetes need careful monitoring if any growth hormone directed therapy is used.
Growth hormone is one voice in a crowded choir
A patient who focuses on growth hormone alone can miss the larger conversation, because the endocrine system works as a set of interacting signals. Testosterone and estrogen both amplify growth hormone secretion, which is one reason the decline in sex hormones after menopause or in the later decades for men coincides with the decline in growth hormone output. Thyroid hormone is required for normal growth hormone production, and an underactive thyroid can mimic or deepen the symptoms attributed to growth hormone deficiency. Cortisol, driven by chronic stress and short sleep, opposes growth hormone in several tissues. The result is that a low IGF-1 can be a consequence of something else, and treating the something else sometimes restores it.
This is why the order of operations matters. A man with fatigue, lost muscle and low libido may have low testosterone, and the practice’s description of what a men’s health consultation covers shows how that is assessed, while the explanation of how age can lower testosterone levels clarifies why it is common. A woman in the menopause transition may have symptoms that overlap with growth hormone decline almost completely, and the difference between bioidentical and conventional hormone therapy is a more relevant starting point for her than any peptide. When people ask whether a peptide approach can help with stubborn weight, it is worth separating the growth hormone axis from the different class of agents used for appetite and glucose control, which the practice addresses in its look at whether peptide therapy works for weight loss. They are different tools with different evidence, and mixing them up leads to disappointment.
Who a careful program is actually for
Candidates fall into recognizable groups, and being honest about the groups protects patients from the wrong door.
People with established or strongly suspected pituitary disease belong with an endocrinologist, who can run stimulation testing and prescribe HGH if deficiency is confirmed. A clinic that offers wellness services should refer these patients rather than treating them in-house.
Healthy adults with symptoms of fatigue, slow recovery and loss of muscle are by far the larger group, and for them the best-supported steps are the unglamorous ones: resistance training with adequate protein, sleep optimization, attention to alcohol, treatment of sleep apnea if present, correction of vitamin D or thyroid abnormalities, and management of weight and blood sugar. If hormone related factors beyond growth hormone are involved, the clinic’s hormone therapy program can address testosterone, estrogen, progesterone and thyroid, and for many patients those are more consequential than growth hormone. Middle aged women may find the overview of when to start hormone therapy useful, and men can see what hormone therapy for men involves.
For some of those patients, a supervised, lower risk program that aims to support the growth hormone axis may be a reasonable adjunct, with realistic expectations. Here the oral medical food approach has a role, provided the patient understands what the product is and is not, the clinic monitors outcomes and the plan includes an off ramp if nothing improves in a defined period.
People who should be cautious or avoid growth hormone directed therapy include those with an active or recent cancer, those with uncontrolled diabetes, women who are pregnant or nursing, and anyone with unexplained symptoms that have not been evaluated. Pituitary or hypothalamic symptoms such as severe headaches, vision changes or loss of several hormones at once call for medical imaging, not supplements.
It also helps to know what a good first visit looks like, so the contrast with a sales appointment is obvious. The clinician should spend most of the time on history: when the symptoms began, what changed around then, how sleep, alcohol, training and eating look in a normal week, which medications and supplements are in use, and whether there is any personal or family history of cancer, diabetes or pituitary disease. A physical assessment follows, often including blood pressure, waist measurement and sometimes body composition. Laboratory orders come next, and treatment options are discussed only after the results are back. If a program is proposed before any of that has happened, the order of events is backward, and it is fair to say so and to wait.
Reading claims critically
The marketplace for growth hormone related products rewards bold promises, and a few patterns signal trouble.
Promises of reversing aging, melting fat without effort or building muscle without training have no support. Reasonable programs talk about support, recovery and gradual change. Claims that a product is “FDA approved” should be checked against the specific category, as discussed above. Testimonials, before and after photos and glowing reviews have value as illustrations, but they are not evidence, and they rarely control for the effect of the diet and training that often accompanies a program. Pricing that locks patients into long prepaid contracts before results can be assessed is another warning sign.
Positive signs include a thorough intake and laboratory workup, written explanations of risks and alternatives, clear criteria for who is not a candidate, defined follow up and a willingness to say that something is not appropriate. The questions that reveal quality are simple. What is this product and how is it regulated? How will we know it is working? What will we do if it is not? Who is supervising me and what are their credentials?
At Ageless Health Institute, the hormone and wellness side of the practice is led clinically by Stephen Noble, PA, a physician assistant with more than ten years of experience focused on hormone therapy, weight management and peptides, and the practice has operated in North Phoenix since 2006. That kind of background is the sort of thing a patient should be able to verify at any clinic, along with who the supervising physician is and how decisions about therapy are made.
Where this fits with the rest of a wellness plan
Growth hormone support does not exist in isolation. A patient who is dealing with menopause, low testosterone, thyroid disease or insulin resistance will usually see a larger change from addressing those directly. The functional and regenerative medicine services at the practice are designed around that broader view, looking at hormones, inflammation, nutrition and lifestyle together. The same is true for body composition goals. Someone who wants to lose fat and keep muscle is often better served by a plan that includes protein targets, resistance training and, where appropriate, medically supervised weight management, with the growth hormone question as a later and smaller consideration.
It is also worth being clear about what a patient can do on their own, at no cost, to support the same pathway. Sleep seven to nine hours in a dark, cool room. Lift heavy things two to three times a week. Eat enough protein, spread across the day. Avoid heavy alcohol, which fragments sleep. Treat snoring and daytime sleepiness seriously, since sleep apnea is common, underdiagnosed and a direct suppressor of growth hormone. Keep a healthy waist circumference. None of these are exciting, and all of them have better evidence than most products. Fatigue that persists despite doing them is a reason to investigate, and the clinic’s piece on fatigue that will not go away outlines the causes worth ruling out.
A sensible way to decide
A decision framework that avoids both hype and dismissal might run like this. Begin with the question of whether there is a medical problem that needs a diagnosis, and if so, pursue that with the right specialist. If the concern is age related change in a generally healthy person, begin with lifestyle foundations and a broad hormone and metabolic evaluation. If the evaluation suggests that growth hormone axis support is a reasonable adjunct, discuss the options with a clinician who explains the regulatory status of each, the limits of evidence and the monitoring plan. Start with the least invasive option that matches the goal. Define in advance how success will be measured, for example grip strength, body composition, sleep quality, recovery time and IGF-1. Reassess at a set interval and stop if there is no meaningful benefit.
That approach respects both the possibility that these programs help some people and the reality that the evidence does not justify the enthusiasm that surrounds them. If you are weighing these options and want a conversation that starts with your history, symptoms and laboratory results rather than a product, you can book an evaluation, and the team can walk through which of the three doors, if any, fits.
Frequently Asked Questions
Is HGH therapy legal for anti-aging in Arizona?
No. Federal law restricts distribution of human growth hormone to FDA approved uses, and anti-aging is not one of them. Legitimate prescribing is limited to diagnosed conditions such as adult growth hormone deficiency.
How is adult growth hormone deficiency diagnosed?
Usually with a stimulation test, where a trigger such as glucagon, insulin-induced low blood sugar or an oral agent is given and growth hormone is measured over time. A low IGF-1 alone is not enough because it falls with age and illness.
What is the difference between HGH and growth hormone releasing peptides?
HGH is the hormone itself, injected from outside. Releasing peptides prompt the pituitary to make its own growth hormone, leaving the body’s feedback loop partly intact. Most releasing peptides are unapproved or compounded.
What is Sarcotropin?
At Ageless Health Institute it is described as a physician directed, orally administered medical food intended to support the body’s own growth hormone release. It is provided through consultation and ongoing care rather than online purchase.
Is a medical food the same as an FDA approved drug?
No. Medical foods are regulated as foods used under physician supervision to manage a disease with distinctive nutritional needs. They are not approved through the drug pathway, so patients should ask what evidence supports the specific product.
What side effects are reported with Sarcotropin?
The practice reports mild digestive discomfort as the most common effect, usually in the first week or two. Anyone with endocrine, digestive or metabolic conditions should have their history reviewed first.
What does HGH do for healthy older adults?
Trials show modest gains in lean mass and reductions in fat mass, without clear gains in strength or quality of life, and with more side effects such as fluid retention, joint pain and raised blood sugar.
Which tests should come before any growth hormone related program?
IGF-1, fasting glucose, hemoglobin A1c, lipids, thyroid function and metabolic panels are typical, often alongside sex hormones, vitamin D and inflammatory markers. Results should be read against age and sex specific ranges.
Can sleep and exercise raise growth hormone naturally?
Yes. Most daily release occurs in deep sleep, and heavy resistance training and high intensity intervals trigger additional pulses. Treating sleep apnea and reducing alcohol also help.
Who should avoid growth hormone directed therapy?
People with active or recent cancer, uncontrolled diabetes, pregnancy or nursing, and those with unexplained symptoms that have not been evaluated should avoid it or proceed only under specialist care.
How long before I would know whether it is working?
Programs should define measurable goals up front, such as recovery time, body composition, sleep and IGF-1, and reassess at a set interval, commonly after about three months. If nothing improves, the plan should be stopped or changed.
Should I see an endocrinologist instead?
If you have pituitary disease, a history of brain surgery or radiation, several hormone deficiencies or unexplained symptoms such as severe headaches or vision changes, yes. Otherwise a wellness clinic can start with lifestyle and a broad evaluation, then refer when needed.
